SBIR/STTR Research Award

The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis

Award identifier fa536949a4d2b42b5a65cc312e630622a9c606fdf8818d8b2875c3bc816d27daAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$143,649

Program and phase

SBIR · Phase I

Award year

2013

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
DIAGNOLOGIX, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
FLYEKQS2YLE7
Solicitation number
PA13-088
Topic code
NCI

Research abstract

Abstract There is an unmet need for cost-efficient technologies for high purity isolation of rare circulating tumor cells (CTCs) from blood. An ideal isolation technique should be able to meet the following criteria: (a) minimal processing time; (b) low final sample volume; (c) isolation from large blood volume; (d) low carryover of leukocytes and blood components; (e) high cell viability; (f) compatibility with downstream processes such as PCR or tissue culturing; (g) low cost and ease of operation by entry-level personnel. While there are numerous approaches for CTC isolation, none of them combines simplicity, low cost, efficiency and speed. Previously, we developed a novel process of buoyant microbubble-assisted isolation of rare tumor cells from blood and buffy coats. MBs efficiently (gt80% recovery) and fast (less than 20 min) isolated rare tumor cells from 7 ml blood or 22 ml buffy coats. For Phase I, Diagnologix, LLC has partnered with the University of California San Diego in order to develop and testa prototype of an intuitive and user-friendly separation/harvesting device that in combination with MBs will be used for harvesting rare tumor cells from complex biological fluids (e.g., blood). The proposed setup will enable easy washing, immunostaining,genetic analysis or culturing of isolated CTCs. The most important competitive advantages of MB approach vs. magnetic beads would be high speed, sample purity, simplicity, flexibility, minimal final sample volume and low cost. The value proposition of thetechnology is in the qualitative and quantitative improvement in CTC isolation and analysis for biomedical and clinical research and potentially for clinical diagnostics. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: The proposal aims to develop a simple to operate and inexpensive device for isolation of rare cell types from blood and other biological fluids. This technology has the potential to improve cancer diagnostics in general population.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

8 SBIR/STTR records share this UEI (2013–2022). Reported award amounts total $7,268,651. Reported amounts are not federal obligations.

Phases: Phase II, Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.